Relay Therapeutics, Inc. (RLAY) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions.
Is Relay Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, Relay Therapeutics, Inc. (RLAY) trades at $18.35 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Relay Therapeutics, Inc.
Market cap $4B · 52 weeks $6 – $21 (12 % below the high) · P/E no earnings · Dividend none · Next earnings November 4, 2026 · expected EPS $-0.40 · Closing price, Oct 30 · accounts published Aug 6.
- Valuation: P/Sales 117.7× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 8.3 %, fails.
- Market cap / Cash 5.7×, fails.
- Cash Runway 28 meses, passes.
- Total Debt 0.1×, passes.
- Annual cash burn $1.37, info.
Against its peers (reference peers) — Relay Therapeutics, Inc.: P/E —; EV/EBITDA —; ROIC -33.7 %; $4.0B. Nurix Therapeutics, Inc. (P/E 11.6×; EV/EBITDA 7.0×; ROIC 25.9 %; $2.9B), Arcutis Biotherapeutics, Inc. (P/E 154×; EV/EBITDA 94.7×; ROIC 9.9 %; $4.0B), Acadia Pharmaceuticals Inc. (P/E 9.3×; EV/EBITDA 27.9×; ROIC 6.2 %; $3.5B).
Profitability
| Return on Equity | -42.27% |
| Return on Invested Capital | -33.72% |
| Return on Assets | -29.57% |
| Gross Margin | -566.59% |
| Operating Margin | -2,999.38% |
| Net Margin | -2,763.64% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 18.27 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 10.99 |
Price Performance
| 1 month | -3.22% |
| 3 months | -2.29% |
| Year-to-date | +116.90% |
| 1 year | +157.00% |
| 3 years | +147.97% |
| 5 years | -47.53% |
Related companies: RVMD · KYMR · ERAS · IDYA · TNGX · NRIX
Explore sector: Healthcare · Biotechnology
More sections of RLAY: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks